Abstract: OBJECTIVE To observe the clinical effects of different antibiotics on treatment of pandrug-resistant Acinetobacter baumannii (PDRAB) infection in ICU so as to provide theoretical basis for the clinical treatment. METHODS A total of 40 patients with PDRAB infection who were treated in the ICU from Jun 2013 to Jun 2015 were enrolled in the study, all of the 40 patients with PDRAB infection were treated with cefoperazone-sulbactam, of whom 18 were given high dose for single therapy, 9-12 g every day, and 22 were treated with cefoperazone-sulbactam combined with levofloxacin or minocycline, with the treatment course (13.3±5.3)days. Totally 10 patients were treated with replacement of polymyxin E due to the poor therapeutic effect, with the treatment course (16.9±5.0)days. The clinical characteristics, use of antibiotics, and clinical therapeutic effect of the patients with PDRAB infections were observed. RESULTS Totally 40 strains of PDRAB were isolated from the deep venous catheter, blood, pus, bronchoalveolar lavage fluid, bile, drainage fluid, and wound secretions that were obtained from the 40 patients; 18 patients had multiple sites of infections. The total effective rate of clinical treatment of the 40 patients with PDRAB infection was 40.0%, the bacterial clearance rate 32.5%, the mortality rate 22.5%. CONCLUSION The high dose of cefoperazone-sulbactam or combination with minocycline can achieve significant clinical effect on treatment of the patients with PDRAB infection, and it is the preferred choice for the treatment of PDRAB infection in China. Polymyxin E can also achieve significant clinical effect on treatment of the PDRAB infection, and it is an effective way to treat the PDRAB infection.